Anti-Human LILRB4/CD85k/ILT3 Reference Antibody (Io-202, RUO) (HV126016)

Name: Anti-Human LILRB4/CD85k/ILT3 Reference Antibody (Io-202, RUO)
Brand: abinScience
SKU: HV126016
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HV126016
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG4, kappa
Biological activity	IO-202 reverses AML cell-mediated T-cell suppression and activates T-cell cytotoxicity against leukemic cells in vitro via high-affinity binding to human LILRB4 and blockade of APOE-mediated LILRB4 activation [1]. IO-202 (15 ug/mL; 2 days) enhances DC activation (increased CD86 and HLA-DR expression) and reduces a tolerogenic phenotype (decreased CD209 expression) when used to treat healthy human donor monocyte-derived dendritic cells during LPS stimulation [3]. IO-202 (15 ug/mL; 2 days during Mo-DC culture, 4 days during T cell co-culture) enhances DC activation marker expression, IL-12 production, and T cell-derived IFNγ production when used to treat human monocyte-derived dendritic cells during CD40L-induced maturation/activation and subsequent allogeneic T cell co-culture, but has no effect on immature Mo-DCs [3]. . IO-202 (10 mg/kg; administered on day 10 and day 20 post tumor implant) combined with 10 Gy radiation therapy induces potent tumor growth inhibition and rebalances the tumor immune infiltrate toward a pro-inflammatory phenotype in a transgenic mouse Lewis lung carcinoma model [3]. . Reduced the frequencies of myeloid-derived suppressor cells (including PMN-MDSCs) among tumor-infiltrating leukocytes. Increased the frequencies of conventional CD4+ T cells and NKT cells among tumor-infiltrating leukocytes. Decreased the expression of the anti-inflammatory marker CD206 on tumor-associated macrophages (TAMs).
Expression system	Mammalian cells
Clonality	Monoclonal
Target	CD85 antigen-like family member K, LIR-5, Leukocyte immunoglobulin-like receptor 5, ILT3, ILT-3, Immunoglobulin-like transcript 3, LILRB4, CD85k, Leukocyte immunoglobulin-like receptor subfamily B member 4, Monocyte inhibitory receptor HM18, LIR5
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q8NHJ6
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	IO-202, IO202, IO202
Background	Leukocyte immunoglobulin-like receptor subfamily B member 4 (CD85k/LILRB4) is a ~49 kDa protein. Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance. Receptor for FN1. Receptor for apolipoprotein APOE. Receptor for ALCAM/CD166. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. 1. Chang, CC. et al. (2002) Nature immunology 3, 237-43. PMID: 11875462 2. Su, MT. et al. (2021) International immunology 33, 447-458. PMID: 34089617 3. Deng, M. et al. (2018) Nature 562, 605-609. PMID: 30333625 4. Xu, Z. et al. (2018) Journal of immunology (Baltimore, Md. : 1950) 200, 1207-1219. PMID: 29263213 5. Cella, M. et al. (1997) The Journal of experimental medicine 185, 1743-51. PMID: 9151699 6. Lu, HK. et al. (2009) The Journal of biological chemistry 284, 34839-48. PMID: 19833736 7. Kim-Schulze, S. et al. (2006) Journal of immunology (Baltimore, Md. : 1950) 176, 2790-8. PMID: 16493035
References	1. DiNardo C D, Pollyea D A, Konopleva M, et al. A first-in-human (FIH) phase 1 study of the anti-LILRB4 antibody IO-202 in relapsed/refractory (R/R) myelomonocytic and monocytic acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (CMML)[J]. Blood, 2020, 136: 19-20. [HV126016] 2. Aribi A, Mannis G, Dunavin N, et al. Targeting LILRB4 (ILT3) using IO-202 in patients with chronic myelomonocytic leukemia (CMML): interim efficacy, safety, and mechanism of action data from the Phase 1b expansion cohort[J]. [HV126016] 3. van der Meer JW, et al. Abstract!. Neth J Med. 2002;60(11):418. [HV126016]
Note	For research use only. Not suitable for clinical or therapeutic use.